CanSino Biologics Inc. announced that the phase I/II clinical trial of the recombinant poliovirus vaccine developed by the company has recently been launched in Indonesia, and the first participant in phase I has been enrolled. This vaccine is a recombinant poliovirus vaccine based on virus-like particles, developed using the company's protein structure design and VLP assembly technology, and is a non-infectious poliovirus vaccine that does not rely on live viruses during production, with expected good safety and immunogenicity.